You have accessJournal of UrologyProstate Cancer: Detection and Screening1 Apr 20111912 DETECTION OF CIRCULATING PROSTATE CANCER CELLS BY MEANS OF AN ANTIBODY-CONJUGATED NANOPARTICULAR BIOSENSOR M. Raschid Hoda, Gerit Theil, Ekkehard Weber, Klaus Lücke, and Paolo Fornara M. Raschid HodaM. Raschid Hoda Halle, Germany More articles by this author , Gerit TheilGerit Theil Halle, Germany More articles by this author , Ekkehard WeberEkkehard Weber Halle, Germany More articles by this author , Klaus LückeKlaus Lücke Potsdam, Germany More articles by this author , and Paolo FornaraPaolo Fornara Halle, Germany More articles by this author View All Author Informationhttps://doi.org/10.1016/j.juro.2011.02.2050AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookTwitterLinked InEmail INTRODUCTION AND OBJECTIVES Currently existing techniques for the isolation of circulating tumor cells (CTC) in blood have experimental approaches. Nanoparticles as biosensors could allow a refinement of the method and possible clinical applicability of the CTC-isolation in cancer patients. METHODS In the framework of a translational project we evaluate the clinical application of a nano-scaled detector conjugated with anti-EpCAM antibody for the isolation of CTCs from peripheral blood of patients with prostate cancer. We reported on the results of preclinical testing. RESULTS The Nano-detector consists of a nano-gold particles loaded on a steel wire. This is coated with anti-EpCAM-AK. At first, the characterization of EpCAM expression in established PCa-cell lines DU 145, PC3 and LNCaP as models for various tumor entities was tested. Cytochemistry showed that all three established cell lines express EpCAM on their cell membrane. The next step was to determine the cell binding efficiency of an anti-EpCAM-functionalized Nano-detectors in the fluid-dynamic system. The cell-binding experiments with cell lines showed a sufficient covalent binding of cells to the detector. For the characterization of the bounded CTCs the multiplex RT-PCR (AdnaTestProstateCancerDetect) was used and the tumor antigens PSMA, PSA, and EGFR were detected. In another step, blood samples from 20 prostate cancer patients of different stages were studied. These blood samples were used in the fluid dynamic system. The characterization of isolated cells was carried out on the RT-PCR with regard to the marker PSMA, PSA, EGFR and at cytochemical level on the detection of EpCAM expression and the control CD45-staining. These were isolated on average of 42.9 CTCs/7.5ml blood sample and in hrPCa, and 3.4 CTCc/7.5ml blood in organ-confined PCA. CONCLUSIONS Isolation of CTCs using an antibody-conjucated nano-scaled-detector in blood of prostate cancer patients of different stages is feasible with high efficiency. The first in-vivo use of this system is currently being tested clinically. © 2011 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 185Issue 4SApril 2011Page: e764-e765 Advertisement Copyright & Permissions© 2011 by American Urological Association Education and Research, Inc.MetricsAuthor Information M. Raschid Hoda Halle, Germany More articles by this author Gerit Theil Halle, Germany More articles by this author Ekkehard Weber Halle, Germany More articles by this author Klaus Lücke Potsdam, Germany More articles by this author Paolo Fornara Halle, Germany More articles by this author Expand All Advertisement Advertisement PDF downloadLoading ...
Read full abstract